OTCShotCaller, could you please weigh in on whether Yesterday's WSJ-Article about Monoclonal Antibodies is using correct facts, where it states that Lilly & Regeneron have human monoclonal antibodies? I had thought ONLY ENZC has the ONLY all-human-all-natural monoclonal antibody COVID-19 cure and holds the Patent for this. Is this your understanding as well? IF so, should we write to WSJ and mention that they are not giving correct information about this to the public and explain why? OR would it be better to alert Charles C. about this error & let him contact WSJ to correct the Article?
Please review my previous Post & kindly offer your professional opinion, which is the best, as you've stated you have worked all your life in the bio-med/bio-tech field with what appears to be impeccable credentials: Thank you!
Here's a copy of my Post:
BonnieMac Member Level Monday, 12/28/20 05:30:13 PM Re: Mistafixit post# 61042 0 Post # 61047 of 61047 Thank you, Mistafixit~ that is what I'd thought~ i.e., ENZC's mAbs (monoclonal antibody patent) starts with a B-Cell taken from a previously infected but now recovered COVID-19 human patient, & uses that as the basis for its cure, whereas these OTHER pharma co's start with a mouse or some other non-human, animal-derivative cell or tissue that they somehow "humanize" or make its immune system to appear like that of a human being.
THEREFORE, I do not believe the writer of this WSJ Article is using correct facts.
Does ANYone else concur with Misafixit's & my "diagnostic" analysis of the matter in this WSJ Article?
Maybe we should write to the WSJ & inform them of true facts about ENZC?
THIS would be a great way for publicity as well, although that was not my intent in pointing out this error in the Article~ I just want the Truth to be published.
News 
Market Data 
Discover 
